Comparative Pharmacology
Head-to-head clinical analysis: CHLOR TRIMETON versus DIPHENHYDRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOR TRIMETON versus DIPHENHYDRAMINE HYDROCHLORIDE.
CHLOR-TRIMETON vs DIPHENHYDRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, thereby preventing histamine-mediated symptoms such as vasodilation, increased capillary permeability, bronchoconstriction, and sensory nerve stimulation.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
4 mg orally every 4-6 hours, not exceeding 24 mg/day. Also available as 8 mg or 12 mg extended-release tablets once daily at bedtime.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults, with clinical context: the antihistamine effect persists longer than plasma levels due to active metabolite production and tissue binding.
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Primarily hepatic metabolism (N-dealkylation and oxidative pathways); renal excretion of metabolites accounts for ~70% of elimination, with <1% excreted unchanged in urine. Fecal elimination is negligible (<5%).
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Category C
Category A/B
Antihistamine
Antihistamine